敗血症診斷市場機會、成長要素、產業趨勢分析及預測（2026年至2035年）

全球敗血症診斷市場預計到 2025 年將達到 8.25 億美元，到 2035 年將達到 23 億美元，年複合成長率為 11%。

這一成長得益於感染疾病率的上升、公共部門對感染控制的日益重視以及診斷技術的不斷進步。臨床醫師和患者對及時診斷重要性的認知不斷提高，也進一步增強了市場需求。抗菌素抗藥性、醫院感染以及慢性病盛行率的不斷上升等因素持續增加敗血症的風險，尤其是在老年人和免疫免疫力缺乏低下患者中。醫療機構越來越重視快速且準確的診斷解決方案，以提高存活率並有效控制治療成本。由於早期發現是改善臨床結果的關鍵，對照護現場診斷和快速診斷工具日益成長的需求為創新和全球市場擴張創造了有利條件。

政府主導的公共衛生基礎設施投資持續推動市場成長。由於感染疾病的進展密切相關，早期檢測已成為公共衛生工作的首要任務。各國醫療保健計畫日益重視改善診斷系統、加強檢測能力和加速臨床決策。這些措施正在推動先進診斷平台的應用，從而增強醫院和實驗室的需求。

預計到2025年，血液培養基市場規模將達到2.821億美元。這些產品旨在促進血液樣本中微生物的生長，從而實現血液感染的檢測。它們與自動化診斷系統的兼容性以及在臨床檢查室的持續應用確保了其穩定的市場需求。由於血液培養基在確診感染疾病發揮著至關重要的作用，因此它仍然是敗血症診斷的核心組成部分。

預計到2025年，基於微生物學的診斷市場規模將達到3.168億美元。該技術專注於從患者檢體中培養和鑑定病原體，並在臨床實踐中廣泛應用。它支持詳細的微生物鑑定和抗菌藥物敏感性測試，這對於制定有效的治療方案和改善患者管理至關重要。

預計到2025年，美國敗血症診斷市場規模將達到2.837億美元。不斷上升的感染率以及老年人和免疫力缺乏低下人群日益成長的脆弱性，持續推動對快速診斷解決方案的需求。強大的醫療基礎設施和先進診斷技術的廣泛應用，為全美市場的持續成長提供了支撐。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章業界考察

• 生態系分析
• 產業影響因素
  • 促進要素
    • 感染疾病率迅速上升
    • 政府加大力度對抗感染疾病
    • 感染疾病診斷的技術進步
    • 人們對感染疾病及其診斷的認知不斷提高
  • 產業潛在風險與挑戰
    • 敗血症診斷設備高成本
    • 嚴格的法規結構
  • 市場機遇
    • 與人工智慧和數位健康相結合
• 成長潛力分析
• 監管環境
• 技術進步
  • 當前技術趨勢
  • 新興技術
• 2024年定價分析
• 未來市場趨勢
• 波特五力分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 公司市佔率分析
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 重大進展
  • 併購
  • 合作夥伴關係和合資企業
  • 新產品發布
  • 擴張計劃

5. 按測試類型分類的市場估算與預測，2022-2035 年

• 血液培養基
• 裝置
• 檢測試劑盒和試劑
• 軟體

第6章 按技術分類的市場估計與預測，2022-2035年

• 微生物學
• 分子診斷
• 免疫檢測
• 流式細胞技術

7. 依方法類型分類的市場估算與預測，2022-2035 年

• 常規診斷
• 自動化診斷

8. 依病原體類型分類的市場估算與預測，2022-2035 年

• 細菌性敗血症
• 黴菌性敗血症
• 其他病原體類型

9. 依最終用途分類的市場估計與預測，2022-2035 年

• 醫院
• 診斷中心
• 診所
• 其他最終用戶

第10章 2022-2035年各地區市場估計與預測

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國

第11章 公司簡介

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific
• Abbott Laboratories
• Beckman Coulter Inc
• Siemens Healthineers
• Becton, Dickinson and Company
• bioMerieux SA
• Bio-Rad Laboratories
• Bruker Corporation
• T2 Biosystems, Inc

The Global Sepsis Diagnostics Market was valued at USD 825 million in 2025 and is estimated to grow at a CAGR of 11% to reach USD 2.3 billion by 2035.

Growth is supported by the rising incidence of infectious diseases, increasing public-sector focus on infection control, and continuous progress in diagnostic technologies. Greater awareness among clinicians and patients regarding the importance of timely diagnosis is further strengthening market demand. Factors such as antimicrobial resistance, hospital-acquired infections, and the expanding prevalence of chronic health conditions continue to elevate sepsis risk, especially among elderly and immunocompromised individuals. Healthcare providers are increasingly prioritizing rapid and accurate diagnostic solutions to improve survival rates and manage treatment costs more effectively. The growing need for point-of-care and faster diagnostic tools is creating favorable conditions for innovation and global market expansion, as early detection remains critical for improving clinical outcomes.

Government-driven investments in public health infrastructure continue to accelerate market growth. Sepsis is closely linked to infectious disease progression, making early identification a public health priority. National healthcare programs increasingly emphasize improved diagnostic readiness, enhanced laboratory capacity, and faster clinical decision-making. These initiatives support wider adoption of advanced diagnostic platforms and strengthen demand across hospital and laboratory settings.

The blood culture media segment generated USD 282.1 million in 2025. These products are formulated to promote the growth of microorganisms from blood samples, enabling the detection of bloodstream infections. Their compatibility with automated diagnostic systems and consistent usage across clinical laboratories ensures stable demand. Blood culture media remain a core component of sepsis diagnostics due to their essential role in confirming infections.

The microbiology-based diagnostics segment accounted for USD 316.8 million in 2025. This approach focuses on cultivating and identifying pathogens from patient samples and remains widely accepted in clinical practice. It supports detailed organism identification and antimicrobial sensitivity analysis, which are essential for guiding effective treatment decisions and improving patient management.

U.S. Sepsis Diagnostics Market was valued at USD 283.7 million in 2025. Rising infection rates and increased vulnerability among aging and immunocompromised populations continue to drive demand for rapid diagnostic solutions. Strong healthcare infrastructure and high adoption of advanced diagnostic technologies support sustained market growth across the country.

Key companies active in the Global Sepsis Diagnostics Market include Abbott Laboratories, Thermo Fisher Scientific, Inc., bioMerieux SA, F. Hoffmann-La Roche Ltd, Siemens Healthineers, Becton, Dickinson and Company, Beckman Coulter Inc (Danaher Corporation), Bio-Rad Laboratories, Bruker Corporation, and T2 Biosystems, Inc. Companies operating in the sepsis diagnostics market focus on multiple strategies to strengthen market position and expand global reach. Continuous investment in research and development enables faster, more sensitive, and more accurate diagnostic solutions. Strategic collaborations with hospitals and research institutions support clinical validation and adoption. Many players expand product portfolios to include rapid and point-of-care testing platforms. Geographic expansion into emerging healthcare markets enhances revenue opportunities. Automation, digital integration, and workflow optimization are prioritized to improve laboratory efficiency.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Test type trends
  • 2.2.3 Product trends
  • 2.2.4 Method trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Surge in prevalence of infectious diseases
    • 3.2.1.2 Increasing government initiatives towards infectious diseases
    • 3.2.1.3 Technological advancements in infectious diseases diagnosis
    • 3.2.1.4 Rising awareness regarding infectious diseases and its diagnosis
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of sepsis diagnostics devices
    • 3.2.2.2 Stringent regulatory framework
  • 3.2.3 Market opportunities
    • 3.2.3.1 Integration with AI & digital health
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technological advancements
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Pricing analysis, 2024
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Test type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Blood culture media
• 5.3 Instruments
• 5.4 Assay kits & reagents
• 5.5 Software

Chapter 6 Market Estimates and Forecast, By Technology, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Microbiology
• 6.3 Molecular diagnostics
• 6.4 Immunoassays
• 6.5 Flow cytometry

Chapter 7 Market Estimates and Forecast, By Method type, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Conventional diagnostics
• 7.3 Automated diagnostics

Chapter 8 Market Estimates and Forecast, By Pathogen type, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Bacterial sepsis
• 8.3 Fungal sepsis
• 8.4 Other pathogen types

Chapter 9 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Diagnostic centers
• 9.4 Clinics
• 9.5 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 India
  • 10.4.3 Japan
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 F. Hoffmann-La Roche Ltd
• 11.2 Thermo Fisher Scientific
• 11.3 Abbott Laboratories
• 11.4 Beckman Coulter Inc
• 11.5 Siemens Healthineers
• 11.6 Becton, Dickinson and Company
• 11.7 bioMerieux SA
• 11.8 Bio-Rad Laboratories
• 11.9 Bruker Corporation
• 11.10 T2 Biosystems, Inc